Becton, Dickinson and Company to establish a plant in China
Introduction:
Global medical technology company, Becton, Dickinson and Company (BD), has announced plans to invest US$16 million to construct a world-class manufacturing plant in China that will produce rapid diagnostic products for flu and viral infections. This, according to the company, is in response to growing demands for clinical testing and rapid diagnosis. BD Rapid Diagnostics (Suzhou) Co., Ltd. will be established in Suzhou Export Processing Zone, District B with a registered capital of US$16 million and a total investment anticipated to reach US$48 million within a few years.
Description
The products to be manufactured at BD Rapid Diagnostics (Suzhou) Co., Ltd. will be able to diagnose a number of bacterial, parasitic, and viral diseases such as influenza, Respiratory Syncytial Virus, HIV, tuberculosis and malaria. These products will be sold to countries and regions around the world, including the US, Japan, Europe, Asia and Latin America.
Recent years have seen frequent outbreaks of contagious diseases, constantly threatening the public's health. Rapid diagnostic products help improve public health programs to address disease control issues and assure people are treated appropriately and effectively. Accurate diagnosis can both result in rapid appropriate treatment and prevent unnecessary use of potentially scarce therapeutics.
BD Rapid Diagnostics (Suzhou) Co., Ltd. is expected to begin production in the fourth fiscal quarter of 2007, with plans to eventually manufacture products to diagnose about 30 infectious diseases.
Specifications Table:
- Name
- BD's world-class manufacturing plant
- Location
- Suzhou Export Processing Zone, District B, China
- Construction Type
- New construction
- Project Starting Year
- June 2006
- Year of Completion
- October 2007
- Estimated Cost
- US$16 million
- Key players
- Beckton, Dickinson & Company
